Investment Analysts’ Weekly Ratings Changes for OncoCyte (OCX)

OncoCyte (NASDAQ: OCX) recently received a number of ratings updates from brokerages and research firms:

• 4/24/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/24/2024 – OncoCyte had its price target raised by analysts at Needham & Company LLC from $3.60 to $4.25. They now have a “buy” rating on the stock.
• 4/18/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/17/2024 – OncoCyte had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $4.00 price target on the stock.
• 4/15/2024 – OncoCyte had its “speculative buy” rating reaffirmed by analysts at Benchmark Co.. They now have a $5.00 price target on the stock.
• 4/12/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/6/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/31/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/25/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/19/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/13/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/7/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/1/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

OncoCyte Stock Performance

NASDAQ OCX traded up $0.04 on Friday, reaching $2.48. The company had a trading volume of 17,519 shares, compared to its average volume of 47,491. OncoCyte Co. has a fifty-two week low of $2.08 and a fifty-two week high of $6.20. The business has a 50 day moving average of $2.90 and a two-hundred day moving average of $3.03.

Insider Activity at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Andrew Arno purchased 33,898 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now directly owns 69,054 shares in the company, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Insiders purchased 2,457,288 shares of company stock worth $7,176,400 over the last three months. Company insiders own 1.94% of the company’s stock.

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.